Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib
Andrew J. Piper‐Vallillo, Daniel B. Costa, Marwa Sabe, Aarti Asnani
Abstract
Incorporation of molecular targeted therapies into the care of patients with sensitizing mutations has driven significant improvements in outcomes in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor ( EGFR )-mutant lung cancer includes the greatest percentage of these cases, and
Topics & Concepts
Epidermal growth factor receptorOsimertinibLung cancerEpidermal growth factorMedicineCancer researchGrowth factor receptor inhibitorMutantInternal medicineOncologyLungReceptorBiologyErlotinibGeneticsGeneLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research